Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Smart Microrobotic Biopsy: A Leap Forward in Brain Disease Diagnostics

Project description

Smart brain biopsies with self-propelled microrobot for in vivo 3D navigation

Each year, approximately 350 000 people are diagnosed with primary brain tumours while another million are afflicted by brain metastases. Accurate diagnosis is crucial to develop treatment strategies and often includes biopsies when imaging techniques are insufficient. Traditional neurosurgical instruments for brain biopsies usually follow direct paths according to the craniotomy incision, and thus may limit access to critical tumour sites. To address this, the EIC-funded SmartMicroBiopsy project is pioneering an active, self-propelled microrobot designed to perform delicate 3D movements for in vivo intracerebral navigation. The project aims to carry out first-in-human clinical trials targeting challenging cases of adult brain tumours, allowing to gather key data for treatment decisions.

Objective

Over 1B people worldwide suffer from brain diseases, including neurodegenerative disorders, cancers, and functional conditions like epilepsy and depression, incurring an annual treatment cost of €1.7T. Specifically in Europe, the cost reached €800B in 2010, increasing each year. Annually, 350k people are diagnosed with primary brain tumours, resulting in 250k deaths. Additionally, brain metastases affect over 1M individuals yearly.
Addressing this socio-economic challenge requires precise medical interventions. Current tools in neurosurgery, such as catheters, needles, and electrodes, are limited to straight paths dictated by the initial skull opening, restricting access to critical tumour sites and thus limiting treatment options.
Robeaute's microrobotics is transforming robotic surgery by enhancing surgical precision and introducing micro and nano techniques for targeting cells directly, facilitating improved diagnostics and treatments. These microrobots perform intricate 3D movements, allowing unprecedented access to critical areas affected by brain diseases. Unlike traditional passive microrobots, which rely on large coils and cannot perform biopsies, Robeaute is pioneering an active, self-propelled microrobot designed for in vivo intracerebral 3D navigation, leading to 54 patent filings.
WIth EIC support, Robeaute aims to conduct First in Human and pivotal clinical trials targeting the brain biopsy market, focusing initially on challenging areas such as paediatric brainstem tumours, recurrent tumours requiring multiple biopsies, primary tumours for comprehensive profiling, and metastases unresponsive to traditional treatments. These specific niches represent a potential market of €0.3B in the US and Europe. The broader biopsy market, valued at €3.67B is expanding with the rise of personalised therapies for brain tumours, necessitating increased biopsy procedures to aid in treatment selection and the development of personalised treatments like cancer vaccines.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

Robeaute
Net EU contribution
€ 2 496 930,63
Address
29 rue du Faubourg Saint-Jacques
75014 Paris
France
SME
Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data